59333-67-4Relevant articles and documents
Truly-Biocompatible Gold Catalysis Enables Vivo-Orthogonal Intra-CNS Release of Anxiolytics
Adam, Catherine,Becker, Catherina G.,Hamilton, Lloyd,Ortega-Liebana, M. Carmen,Porter, Nicola J.,Sieger, Dirk,Unciti-Broceta, Asier,Valero, Teresa
supporting information, (2021/11/22)
Being recognized as the best-tolerated of all metals, the catalytic potential of gold (Au) has thus far been hindered by the ubiquitous presence of thiols in organisms. Herein we report the development of a truly-catalytic Au-polymer composite by assembling ultrasmall Au-nanoparticles at the protein-repelling outer layer of a co-polymer scaffold via electrostatic loading. Illustrating the in vivo-compatibility of the novel catalysts, we show their capacity to uncage the anxiolytic agent fluoxetine at the central nervous system (CNS) of developing zebrafish, influencing their swim pattern. This bioorthogonal strategy has enabled -for the first time- modification of cognitive activity by releasing a neuroactive agent directly in the brain of an animal.
Copper-catalyzed and additive free decarboxylative trifluoromethylation of aromatic and heteroaromatic iodides
Johansen, Martin B.,Lindhardt, Anders T.
, p. 1417 - 1425 (2020/03/03)
A copper-catalyzed decarboxylative trifluoromethylation of (hetero)aromatic iodides has been developed. Importantly, this new copper-catalyzed reaction operates in the absence of any ligands and metal additives. The protocol shows good functional group tolerance and is compatible with heteroaromatic systems. The reaction proved scalable to a 15 mmol scale with increased yield. Finally, late-stage installation of the trifluoromethyl functionality afforded the N-trifluoroacetamide variant of the antidepressant agent, Prozac, demonstrating the applicability of the developed method.
Determination of fluoxetine hydrochloride via ion-pair complexation with alizarin red S
Constantinescu, Ioana Clementina,Neagu, Alexandra Filareta,Uivarosi, Valentina
, p. 1293 - 1303 (2019/01/04)
Two UV-Vis spectrophotometric methods and one fluorimetric method have been developed for the quantitative determination of fluoxetine hydrochloride in bulk and pharmaceutical formulations. These methods are based on the ion-pair complex formation between alizarin red S and fluoxetine hydrochloride. In the first method (method A), the yellow-colored complex obtained in acidic medium was extracted with chloroform and the absorbance of the chloroformic solution was measured at 425 nm. Beerís law limits (9.5 ? 48 μg/mL), the molar absorptivity (5256 L ∑ mol-1 ∑ cm-1), and the complex composition (1: 1) were determined. In the second method (method B), the yellow complex fluoxetine ? alizarin red S extracted in chloroform was broken in alkaline medium, and the absorbance of the resulting violet-colored free dye was measured at 524 nm. A linear relationship was observed in the range of 9.0 ? 54 μg/mL. In the third method (method C) the fluorescence intensity of the fluoxetine ? alizarin red S complex, obtained in the same manner as for method A, was measured at 594 nm after excitation at 425 nm. The fluorescence intensity was proportional to the drug concentration in the linear range of 2.7-10.2 μg/mL. The limits of detection and quantification have also been calculated. Furthermore, the proposed methods have been successfully applied for the assay of the drug in pharmaceutical dosage forms.
